IL136454A0 - Compositions and methods for inducing gene expression - Google Patents
Compositions and methods for inducing gene expressionInfo
- Publication number
- IL136454A0 IL136454A0 IL13645498A IL13645498A IL136454A0 IL 136454 A0 IL136454 A0 IL 136454A0 IL 13645498 A IL13645498 A IL 13645498A IL 13645498 A IL13645498 A IL 13645498A IL 136454 A0 IL136454 A0 IL 136454A0
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- gene expression
- inducing gene
- inducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6754697P | 1997-12-04 | 1997-12-04 | |
US13361298A | 1998-08-13 | 1998-08-13 | |
PCT/US1998/025753 WO1999028469A1 (en) | 1997-12-04 | 1998-12-04 | Compositions and methods for inducing gene expression |
Publications (1)
Publication Number | Publication Date |
---|---|
IL136454A0 true IL136454A0 (en) | 2001-06-14 |
Family
ID=26747998
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13645498A IL136454A0 (en) | 1997-12-04 | 1998-12-04 | Compositions and methods for inducing gene expression |
IL136454A IL136454A (en) | 1997-12-04 | 2000-05-30 | Compositions and methods for inducing gene expression |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL136454A IL136454A (en) | 1997-12-04 | 2000-05-30 | Compositions and methods for inducing gene expression |
Country Status (9)
Country | Link |
---|---|
US (3) | US6432927B1 (xx) |
EP (1) | EP1034267A1 (xx) |
JP (2) | JP2001525173A (xx) |
AU (1) | AU749467B2 (xx) |
CA (1) | CA2311643C (xx) |
IL (2) | IL136454A0 (xx) |
NO (1) | NO20002849L (xx) |
NZ (1) | NZ504847A (xx) |
WO (1) | WO1999028469A1 (xx) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2311643C (en) * | 1997-12-04 | 2009-04-07 | Genzyme Corporation | Compositions and methods for inducing gene expression |
US6124131A (en) * | 1998-08-25 | 2000-09-26 | The Johns Hopkins University School Of Medicine | Mutant hypoxia inducible factor-1 HIF-1 |
FR2801319A1 (fr) * | 1999-11-18 | 2001-05-25 | Inst Nat Sante Rech Med | Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene |
WO2001062965A2 (en) * | 2000-02-22 | 2001-08-30 | Oxford Biomedica (Uk) Limited | Differential expression screening method |
US7214770B2 (en) | 2000-07-06 | 2007-05-08 | Angiogenetics Sweden Ab | Screening Methods |
SE0002551D0 (sv) * | 2000-07-06 | 2000-07-06 | Pharmacia & Upjohn Ab | Screening methods |
AU2001290179B2 (en) * | 2000-08-07 | 2007-07-12 | Angiogenetics Sweden Ab | Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein |
DE10154224A1 (de) * | 2000-11-07 | 2002-06-20 | Max Delbrueck Centrum | Anwendung herzspezifischer Transkriptionsfaktoren vom basischen Helix-Loop-Helix-Typ zur Behandlung der Herzinsuffizienz |
US7109029B2 (en) | 2001-02-23 | 2006-09-19 | Cell Genesys, Inc. | Vector constructs |
GB0107757D0 (en) * | 2001-03-28 | 2001-05-16 | Gendaq Ltd | Gene regulation II |
WO2003045440A1 (en) * | 2001-11-28 | 2003-06-05 | Angiogenetics Sweden Ab | Regulation of hypoxia-inducible gene expression with antisense inhibitory pas domain protein |
CA3094774A1 (en) * | 2001-12-06 | 2003-07-03 | Fibrogen, Inc. | Use of hif prolyl hydroxylase inhibitors for treating neurological disorders |
US7527942B2 (en) | 2002-02-08 | 2009-05-05 | The Regents Of The University Of California | Transcription amplification system for molecular imaging |
DE10245926B4 (de) * | 2002-10-02 | 2005-04-07 | Ab Elektronik Gmbh | Bodenpedal mit Drehwinkelsensor |
US7371570B2 (en) | 2002-11-01 | 2008-05-13 | Cell Genesys, Inc. | Cell-specific adenovirus vector comprising EBV-specific promoter |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
US7618940B2 (en) * | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
US20050037390A1 (en) * | 2003-06-04 | 2005-02-17 | Irm Llc, A Delaware Limited Liability Company | Methods and compositions for modulating erythropoietin expression |
US8614204B2 (en) * | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
US7822276B2 (en) * | 2005-02-17 | 2010-10-26 | Iris International, Inc. | Method and apparatus for analyzing body fluids |
AU2006259352A1 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of HIF 1alfa modulators for treatment of cancer |
WO2007048004A2 (en) | 2005-10-21 | 2007-04-26 | Cornell Research Foundation, Inc. | Compounds for enhancing hypoxia inducible factor activity and methods of use |
EP2005752A4 (en) * | 2006-03-30 | 2010-06-09 | Lg Electronics Inc | METHOD AND APPARATUS FOR DECODING / ENCODING A VIDEO SIGNAL |
US7759306B2 (en) * | 2006-05-16 | 2010-07-20 | Simoni Jan S | Methods of treating acute blood loss |
PL2029742T3 (pl) | 2006-06-07 | 2017-08-31 | Genzyme Corporation | Terapia genowa w stwardnieniu zanikowym bocznym i innych zaburzeniach rdzenia kręgowego |
WO2008033304A2 (en) * | 2006-09-12 | 2008-03-20 | Genzyme Corporation | Compositions for promoting non-leaky collateral vascularization |
US20080081354A1 (en) * | 2006-10-02 | 2008-04-03 | Cardiac Pacemakers, Inc. | Devices, vectors and methods for inducible ischemia cardioprotection |
DK2497500T3 (da) | 2006-10-03 | 2017-01-02 | Genzyme Corp | Genterapi mod spinal muskelatrofi |
US8846053B2 (en) | 2008-09-26 | 2014-09-30 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
US9145453B2 (en) * | 2007-09-28 | 2015-09-29 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
US8962015B2 (en) * | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
PT3421603T (pt) | 2009-05-02 | 2022-01-10 | Genzyme Corp | Terapia génica para distúrbios neurodegenerativos |
JP2012527480A (ja) * | 2009-05-21 | 2012-11-08 | ステムサイト インコーポレイテッド | 脳組織の損傷の細胞療法 |
RU2662672C2 (ru) | 2012-02-02 | 2018-07-26 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Пестицидные композиции и относящиеся к ним способы |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8059891A (en) | 1990-06-13 | 1992-01-07 | Trustees Of Princeton University, The | A (lac) repressor-hsv vp16 chimeric transcriptional activator protein system functioning in transfected mammalian cells |
CA2098849C (en) * | 1990-12-20 | 2007-07-10 | Ralph R. Weichselbaum | Control of gene expression by ionizing radiation |
US5962427A (en) * | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
US5834306A (en) * | 1994-12-23 | 1998-11-10 | Sri International | Tissue specific hypoxia regulated therapeutic constructs |
CN1136920C (zh) * | 1995-02-28 | 2004-02-04 | 加利福尼亚大学董事会 | 基因转移介导的血管形成疗法 |
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
US5882914A (en) * | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
US6306649B1 (en) * | 1995-06-27 | 2001-10-23 | Ariad Gene Therapeutics, Inc. | Heterologous transcription factors |
US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
US5695963A (en) * | 1997-01-17 | 1997-12-09 | Board Of Regents, The University Of Texas System | Endothelial PAS domain protein |
WO1998056936A1 (en) | 1997-06-10 | 1998-12-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulatory sequences involved in hypoxia regulated gene expression and uses thereof |
US6087166A (en) * | 1997-07-03 | 2000-07-11 | Basf Aktiengesellschaft | Transcriptional activators with graded transactivation potential |
CA2311643C (en) * | 1997-12-04 | 2009-04-07 | Genzyme Corporation | Compositions and methods for inducing gene expression |
US6124131A (en) * | 1998-08-25 | 2000-09-26 | The Johns Hopkins University School Of Medicine | Mutant hypoxia inducible factor-1 HIF-1 |
-
1998
- 1998-12-04 CA CA002311643A patent/CA2311643C/en not_active Expired - Fee Related
- 1998-12-04 AU AU16268/99A patent/AU749467B2/en not_active Ceased
- 1998-12-04 IL IL13645498A patent/IL136454A0/xx unknown
- 1998-12-04 EP EP98960741A patent/EP1034267A1/en not_active Withdrawn
- 1998-12-04 NZ NZ504847A patent/NZ504847A/xx unknown
- 1998-12-04 WO PCT/US1998/025753 patent/WO1999028469A1/en active IP Right Grant
- 1998-12-04 JP JP2000523345A patent/JP2001525173A/ja active Pending
-
2000
- 2000-05-26 US US09/579,897 patent/US6432927B1/en not_active Expired - Lifetime
- 2000-05-30 IL IL136454A patent/IL136454A/en not_active IP Right Cessation
- 2000-06-02 NO NO20002849A patent/NO20002849L/no not_active Application Discontinuation
-
2002
- 2002-07-03 US US10/190,394 patent/US7053062B2/en not_active Expired - Lifetime
-
2006
- 2006-02-13 US US11/352,879 patent/US20060127361A1/en not_active Abandoned
-
2007
- 2007-02-21 JP JP2007040987A patent/JP2007195555A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2311643C (en) | 2009-04-07 |
EP1034267A1 (en) | 2000-09-13 |
AU1626899A (en) | 1999-06-16 |
NO20002849D0 (no) | 2000-06-02 |
IL136454A (en) | 2010-06-16 |
CA2311643A1 (en) | 1999-06-10 |
US6432927B1 (en) | 2002-08-13 |
US7053062B2 (en) | 2006-05-30 |
JP2001525173A (ja) | 2001-12-11 |
NZ504847A (en) | 2003-02-28 |
WO1999028469A1 (en) | 1999-06-10 |
NO20002849L (no) | 2000-08-02 |
AU749467B2 (en) | 2002-06-27 |
US20060127361A1 (en) | 2006-06-15 |
US20030018007A1 (en) | 2003-01-23 |
JP2007195555A (ja) | 2007-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL136454A0 (en) | Compositions and methods for inducing gene expression | |
SG105505A1 (en) | Gene sequencer and methods | |
IL132704A0 (en) | Methods and compositions for the selective modification of nucleic acids | |
EP1003916A4 (en) | ANTI-SENSE OLIGONUCLEOTID COMPOSITIONS AND METHODS FOR MODULATING JNK PROTEINS | |
AU9692198A (en) | Gene delivery compositions and methods | |
GB9622500D0 (en) | Therapeutic gene | |
IL135338A0 (en) | Methods and compositions for the selective modification of nucleic acids | |
EP1165586A4 (en) | TCL-1B GENES AND PROTEINS AND RELATED METHODS AND METHODS | |
HUP0003745A3 (en) | Methods and compositions for inducing tumor-specific cytotoxicity | |
HUP0100535A3 (en) | Hydrophobically-modified protein compositions and methods | |
ZA989399B (en) | Method and composition | |
AU1390199A (en) | Compositions and methods for inhibiting the activity of certain genes | |
HUP0101701A3 (en) | Substituted betha-alanines and pharmaceutical compositions comprising them | |
ZA979295B (en) | Methods and compositions for delivery and expression of interferon-Ó nucleic acids. | |
ZA9710934B (en) | Compositions and methods for administering pneumococal dna | |
EP1007726A4 (en) | METHOD AND COMPOSITIONS FOR REGULATING GENE EXPRESSION | |
EP0987942A4 (en) | PHARMACEUTICAL COMPOSITION AND METHOD OF USE | |
EP1163340A4 (en) | COMPOSITIONS AND METHODS FOR MODIFYING GENE EXPRESSION | |
EP0976720A4 (en) | propanolamine | |
EP1038957A4 (en) | GENE TSA305 | |
AU9393798A (en) | Genetic compositions and methods | |
AU8513698A (en) | Methods and compositions for designing vaccines | |
AU7287798A (en) | Compositions and methods for bioremediation | |
GB9706469D0 (en) | Genetic method | |
GB9724828D0 (en) | Gene |